Trump Signs Order to Speed Psychedelic Research, Including Ibogaine

President Trump signed an executive order Saturday meant to speed research and review of psychedelic drugs for mental health treatment, with a focus on ibogaine, CBS News and the Associated Press reported. Health Secretary Robert F. Kennedy Jr., other health officials, podcaster Joe Rogan and former Navy SEAL Marcus Luttrell joined him in the Oval Office.

“Today’s order will ensure that people suffering from debilitating symptoms might finally have a chance to reclaim their lives,” Mr. Trump said, according to the AP. He said the government will make a $50 million research investment and open a path for ibogaine to be given to “desperately ill patients” under the Food and Drug Administration’s Right to Try rule, CBS News reported. FDA Commissioner Marty Makary said three psychedelics will be added to the agency’s National Priority Voucher program, which can cut review times from months to weeks. The AP said it is the first time the FDA has offered that fast track to any psychedelic. The FDA will also begin the process of allowing human trials of ibogaine in the U.S.

Ibogaine, made from a West African shrub, remains a Schedule I substance, grouped with heroin by the Drug Enforcement Administration, and the order does not change that. Former Surgeon General Jerome Adams, who served in Mr. Trump’s first term, said on CBS’s “Face the Nation” that the order keeps full FDA and DEA oversight and does not legalize or reclassify the drugs, CBS News reported. Veterans’ groups and some conservative lawmakers have embraced ibogaine for post-traumatic stress and opioid addiction, and the AP described the issue as one with rare bipartisan support. Mr. Trump highlighted veterans’ suicide rates.

The science is early. CBS News reported that the evidence so far consists mostly of small observational studies and open-label trials, with only one double-blind, placebo-controlled randomized trial completed, and that larger trials have only recently begun. Americans have been traveling to unregulated clinics abroad to take the drug, CBS News said. Adams said early studies show “potential for rapid improvements in symptoms and functioning in treatment-resistant cases.”

The AP stressed the risks. Ibogaine is known to sometimes trigger potentially fatal heart problems, and the National Institutes of Health briefly funded research on it in the 1990s but dropped the work over its “cardiovascular toxicity.” Frederick Barrett, director of the Johns Hopkins Center for Psychedelic and Consciousness Research, said it has been “incredibly difficult to study ibogaine in the U.S. because of its known cardiotoxicity,” but that an order that paves the way for “objective, scientific research” would help determine whether it is a better therapy than others. The AP said the order surprised many longtime advocates and researchers.

No psychedelic has been approved in the U.S., though psilocybin, MDMA and LSD are in large trials, according to the AP. Oregon and Colorado have legalized some use under state law. CBS News said the details of how the federal government will help fund and facilitate research were still being worked out in internal discussions this week.